Developer docs
API playgroundTry for free, no card

Search company profiles

Q Therapeutics

Full company profile

uuid00026n7

Namestring
Q Therapeutics
Legal namestring
Q Therapeutics, Inc.
Websiteurl
qthera.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Q Therapeutics, Inc. is a privately-held clinical-stage biotechnology company headquartered in Salt Lake City, Utah, developing allogeneic cell-based therapeutics for currently incurable central nervous system (CNS) diseases. The company's sole clinical asset is Q-Cells®, a population of human glial-restricted progenitor (GRP) cells isolated and purified from brain tissue without genetic manipulation. Q-Cells® are designed as an off-the-shelf injectable that, upon administration to the CNS, migrate to sites of injury or disease and differentiate into astrocytes and oligodendrocytes — the support cells responsible for maintaining myelin and neuronal function. The company holds 21 issued patents across five patent families and has received FDA Fast Track and Orphan Drug Designation for ALS (November 2013) and Orphan Drug Designation for Transverse Myelitis (September 2018); FDA IND clearance for ALS was granted in June 2015 and IND allowance for a Phase 1/2a Transverse Myelitis trial followed in July 2017.

The pipeline is anchored by Q-Cells® for ALS (30-patient dose-escalating first-in-human trial) and Transverse Myelitis (9-patient dose-escalating trial), with future indications including Multiple Sclerosis (~400,000 U.S. patients) and spinal cord injury (~12,000 new U.S. cases annually). The company also holds an exclusive worldwide license to Q-Cells® from the University of Utah Research Foundation and has established a joint venture with REPROCELL — MAGiQ Therapeutics — to advance commercialization, alongside research collaborations with Johns Hopkins University, the Buck Institute, and InVivo Therapeutics. In November 2016, Q Therapeutics acquired Degania Medical, marking a diversification into medical devices. The company has fewer than 10 employees, is led by CEO/Chairman Steven Borst with Scientific Co-founder Mahendra Rao (former NIH Center for Regenerative Medicine Director) as CSO, and has raised approximately $24.2 million across disclosed funding rounds between 2008 and 2017.

As a pre-revenue clinical-stage biotech, Q Therapeutics' revenue mechanics will ultimately depend on commercialization of Q-Cells® (likely through the MAGiQ JV or a future pharma partnership), with pricing not publicly disclosed. Current customer segments are defined by indication — ALS patients (~30,000 U.S.), Transverse Myelitis patients (~44,000 U.S.), and future MS and SCI populations — and there are no named commercial customers or distribution channels today. Marketing activity is limited to scientific publications, press releases, and investor relations rather than consumer channels, consistent with a pre-commercial biotech.

Short descriptiontext

Q Therapeutics is a privately-held clinical-stage biotechnology company developing Q-Cells®, an allogeneic human glial progenitor cell therapy for incurable central nervous system diseases including ALS, transverse myelitis, multiple sclerosis, and spinal cord injury.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy, regenerative medicine, glial progenitor cells, CNS therapeutics, neurodegenerative disease treatment
Industry3 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Regenerative Medicine for CNS Diseases
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Q-Cells®
Description

Human glial progenitor cells that give rise to astrocytes and oligodendrocytes, the company's first cellular therapeutic candidate for treating CNS diseases including Transverse Myelitis and ALS.

qthera.com
Core offering1 text field

Q Therapeutics develops Q-Cells®, an allogeneic human glial progenitor cell therapeutic candidate designed to treat incurable central nervous system (CNS) diseases by delivering healthy glial-restricted progenitor cells to sites of CNS injury. Q-Cells® differentiate into astrocytes and oligodendrocytes to replace damaged myelin-producing and neuron-supporting cells, and are intended for treatment of transverse myelitis, ALS, multiple sclerosis, and spinal cord injury through injection-based administration. The company is clinical-stage with FDA-cleared Phase 1/2a trials in ALS and Transverse Myelitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • No observed toxicity in more than 360 treated animals across six independent laboratories
+1 more record
Product overview1 text field

Q Therapeutics is developing Q-Cells®, an allogeneic human glial progenitor cell therapy for treating incurable central nervous system (CNS) diseases. Q-Cells® are adult progenitor cells restricted in their ability to differentiate only into glia (astrocytes and oligodendrocytes), providing support and repair functions for neurons. The company is advancing clinical trials for Transverse Myelitis and ALS, with pipeline candidates targeting Multiple Sclerosis, Spinal Cord Injury, and other neurodegenerative diseases.

Product and service1 record
1Q-Cells® Glial Progenitor Cell Therapeutic
CategoryCell Therapy / Regenerative Medicine
Description

Allogeneic, off-the-shelf human glial progenitor cell therapeutic that gives rise to astrocytes and oligodendrocytes. Designed to be delivered via small-volume injection to sites of central nervous system injury or disease to restore myelin production and neuron support functions. FDA Fast Track and Orphan Drug designated for ALS; Orphan Drug designated for Transverse Myelitis.

Partnership6 partners
1InVivo Therapeutics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-10-02
Description

Joint research collaboration announced October 2018 focused on stem cell therapeutic approaches for spinal cord repair.

qthera.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-04-23
Description

Joint venture partnership with REPROCELL to develop and commercialize cell therapies. Also established MAGiQ Therapeutics as a joint venture entity.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-12-13
Description

Research collaboration to study neural cell therapies for neurological disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-10-21
Description

Long-standing collaboration with Johns Hopkins researchers on study of human neural glial cells in treatment of ALS. Multiple joint studies and NIH funding received through this partnership.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2008-04-14
Description

Stem cell collaboration to combat Parkinson's disease using Q-Cells technology.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive worldwide rights to Q-Cells® product through agreement with University of Utah Research Foundation, based on technology developed by Dr. Mahendra Rao during his tenure at the University.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BrainStorm develops NurOwn®, an autologous MSC-based cell therapy for ALS and MS — the closest direct peer to Q-Cells as a CNS-focused cell therapy developer. Both companies target neurodegenerative demyelination/motor neuron rescue with cell-based approaches.

TypeDirect peer
Description

Neuralstem developed NSI-566, a human neural stem cell therapy for ALS, and pursued CNS regenerative indications — directly comparable platform, target indication, and cell type to Q-Cells' approach.

TypeDirect peer
Description

Lineage develops oligodendrocyte progenitor cell therapies (e.g., OPC1 for spinal cord injury) and other allogeneic CNS cell therapies, making it one of the closest mechanistic and indication peers to Q Therapeutics' glial progenitor platform.

TypeEmerging player
Description

Celavie develops human neural stem cell therapies for CNS disorders including Parkinson's disease, representing an emerging cell-therapy peer with overlapping CNS regenerative focus but more limited public visibility and capital.

TypeEmerging player
Description

BlueRock (a Bayer subsidiary) develops engineered iPSC-derived cell therapies for neurological diseases including Parkinson's. Comparable as a well-capitalized CNS cell therapy peer, though differentiated by pluripotent vs. progenitor cell source and genetic engineering.

6Athersys
TypeEmerging player
Description

Athersys develops MultiStem®, an off-the-shelf allogeneic stem cell therapy evaluated in stroke and ARDS — comparable as a clinical-stage allogeneic cell therapy company, though focused on different CNS/critical care indications.

TypeBroad incumbent
Description

Amylyx developed AMX0035/Relyvrio for ALS, a small-molecule alternative to cell therapy in the same primary indication. Comparable as a focused ALS therapeutic developer pursuing the same patient population with different modality.

TypeBroad incumbent
Description

Cytokinetics develops muscle-targeted small molecules (e.g., reldesemtiv/ tirasemtiv) for ALS and other neuromuscular diseases, competing for the same ALS patient population through a non-cell-therapy approach with broader pipeline scale.

TypeBroad incumbent
Description

Biogen is a dominant neurology biopharmaceutical with major franchises in Multiple Sclerosis (Tysabri, Tecfidera) and ALS assets (Qalsody/tofersen). Represents the broad incumbent against which Q-Cells would compete in MS and ALS commercialization.

10InVivo Therapeutics
TypeDirect peer
Description

InVivo Therapeutics develops implantable scaffolds and cellular therapies for spinal cord injury and is a named research collaborator of Q Therapeutics since October 2018. Directly comparable in CNS/spinal cord injury therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q Therapeutics

Cell Therapy / Regenerative Medicine for CNS Diseasesqthera.com

Q Therapeutics is a privately-held clinical-stage biotechnology company developing Q-Cells®, an allogeneic human glial progenitor cell therapy for incurable central nervous system diseases including ALS, transverse myelitis, multiple sclerosis, and spinal cord injury.

What Q Therapeutics does

Q Therapeutics, Inc. is a privately-held clinical-stage biotechnology company headquartered in Salt Lake City, Utah, developing allogeneic cell-based therapeutics for currently incurable central nervous system (CNS) diseases. The company's sole clinical asset is Q-Cells®, a population of human glial-restricted progenitor (GRP) cells isolated and purified from brain tissue without genetic manipulation. Q-Cells® are designed as an off-the-shelf injectable that, upon administration to the CNS, migrate to sites of injury or disease and differentiate into astrocytes and oligodendrocytes — the support cells responsible for maintaining myelin and neuronal function. The company holds 21 issued patents across five patent families and has received FDA Fast Track and Orphan Drug Designation for ALS (November 2013) and Orphan Drug Designation for Transverse Myelitis (September 2018); FDA IND clearance for ALS was granted in June 2015 and IND allowance for a Phase 1/2a Transverse Myelitis trial followed in July 2017.

The pipeline is anchored by Q-Cells® for ALS (30-patient dose-escalating first-in-human trial) and Transverse Myelitis (9-patient dose-escalating trial), with future indications including Multiple Sclerosis (~400,000 U.S. patients) and spinal cord injury (~12,000 new U.S. cases annually). The company also holds an exclusive worldwide license to Q-Cells® from the University of Utah Research Foundation and has established a joint venture with REPROCELL — MAGiQ Therapeutics — to advance commercialization, alongside research collaborations with Johns Hopkins University, the Buck Institute, and InVivo Therapeutics. In November 2016, Q Therapeutics acquired Degania Medical, marking a diversification into medical devices. The company has fewer than 10 employees, is led by CEO/Chairman Steven Borst with Scientific Co-founder Mahendra Rao (former NIH Center for Regenerative Medicine Director) as CSO, and has raised approximately $24.2 million across disclosed funding rounds between 2008 and 2017.

As a pre-revenue clinical-stage biotech, Q Therapeutics' revenue mechanics will ultimately depend on commercialization of Q-Cells® (likely through the MAGiQ JV or a future pharma partnership), with pricing not publicly disclosed. Current customer segments are defined by indication — ALS patients (~30,000 U.S.), Transverse Myelitis patients (~44,000 U.S.), and future MS and SCI populations — and there are no named commercial customers or distribution channels today. Marketing activity is limited to scientific publications, press releases, and investor relations rather than consumer channels, consistent with a pre-commercial biotech.

Q Therapeutics firmographics

Firmographics
Name
Q Therapeutics
Legal name
Q Therapeutics, Inc.
Website
https://qthera.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Q Therapeutics is a privately-held clinical-stage biotechnology company developing Q-Cells®, an allogeneic human glial progenitor cell therapy for incurable central nervous system diseases including ALS, transverse myelitis, multiple sclerosis, and spinal cord injury.
Ownership category
akta.pro rank

Q Therapeutics industry classification

Industry
Product category
Cell Therapy / Regenerative Medicine for CNS Diseases
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology

Keywords

  • Cell therapy
  • Regenerative medicine
  • Glial progenitor cells
  • CNS therapeutics
  • Neurodegenerative disease treatment

Where Q Therapeutics is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Q Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Marketing channels5 records

Q Therapeutics product offering

Product offering

Core offering

Q Therapeutics develops Q-Cells®, an allogeneic human glial progenitor cell therapeutic candidate designed to treat incurable central nervous system (CNS) diseases by delivering healthy glial-restricted progenitor cells to sites of CNS injury. Q-Cells® differentiate into astrocytes and oligodendrocytes to replace damaged myelin-producing and neuron-supporting cells, and are intended for treatment of transverse myelitis, ALS, multiple sclerosis, and spinal cord injury through injection-based administration. The company is clinical-stage with FDA-cleared Phase 1/2a trials in ALS and Transverse Myelitis.

Product overview

Q Therapeutics is developing Q-Cells®, an allogeneic human glial progenitor cell therapy for treating incurable central nervous system (CNS) diseases. Q-Cells® are adult progenitor cells restricted in their ability to differentiate only into glia (astrocytes and oligodendrocytes), providing support and repair functions for neurons. The company is advancing clinical trials for Transverse Myelitis and ALS, with pipeline candidates targeting Multiple Sclerosis, Spinal Cord Injury, and other neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • Q-Cells®: Human glial progenitor cells that give rise to astrocytes and oligodendrocytes, the company's first cellular therapeutic candidate for treating CNS diseases including Transverse Myelitis and ALS.

Products and services

  • Q-Cells® Glial Progenitor Cell Therapeutic Allogeneic, off-the-shelf human glial progenitor cell therapeutic that gives rise to astrocytes and oligodendrocytes. Designed to be delivered via small-volume injection to sites of central nervous system injury or disease to restore myelin production and neuron support functions. FDA Fast Track and Orphan Drug designated for ALS; Orphan Drug designated for Transverse Myelitis.

Quantifiable outcome

  • No observed toxicity in more than 360 treated animals across six independent laboratories
  • +1 more outcomes

Companies that use Q Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Q Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Q Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • InVivo TherapeuticsminorStrategic or Co-development Partner · 2 October 2018Joint research collaboration announced October 2018 focused on stem cell therapeutic approaches for spinal cord repair.
  • REPROCELLcoreStrategic or Co-development Partner · 23 April 2018Joint venture partnership with REPROCELL to develop and commercialize cell therapies. Also established MAGiQ Therapeutics as a joint venture entity.
  • REPROCELLminorStrategic or Co-development Partner · 13 December 2017Research collaboration to study neural cell therapies for neurological disorders.
  • Johns Hopkins UniversitycoreStrategic or Co-development Partner · 21 October 2008Long-standing collaboration with Johns Hopkins researchers on study of human neural glial cells in treatment of ALS. Multiple joint studies and NIH funding received through this partnership.
  • Buck InstituteminorStrategic or Co-development Partner · 14 April 2008Stem cell collaboration to combat Parkinson's disease using Q-Cells technology.
  • University of Utah Research FoundationcoreTechnology or IntegrationExclusive worldwide rights to Q-Cells® product through agreement with University of Utah Research Foundation, based on technology developed by Dr. Mahendra Rao during his tenure at the University.

Recent moves6 records

Expansion highlights5 records

Q Therapeutics competitors and assessment

Company assessment

Direct peers

  • BrainStorm Cell Therapeutics: BrainStorm develops NurOwn®, an autologous MSC-based cell therapy for ALS and MS — the closest direct peer to Q-Cells as a CNS-focused cell therapy developer. Both companies target neurodegenerative demyelination/motor neuron rescue with cell-based approaches.
  • Neuralstem (Seneca Biopharma): Neuralstem developed NSI-566, a human neural stem cell therapy for ALS, and pursued CNS regenerative indications — directly comparable platform, target indication, and cell type to Q-Cells' approach.
  • Lineage Cell Therapeutics: Lineage develops oligodendrocyte progenitor cell therapies (e.g., OPC1 for spinal cord injury) and other allogeneic CNS cell therapies, making it one of the closest mechanistic and indication peers to Q Therapeutics' glial progenitor platform.
  • InVivo Therapeutics: InVivo Therapeutics develops implantable scaffolds and cellular therapies for spinal cord injury and is a named research collaborator of Q Therapeutics since October 2018. Directly comparable in CNS/spinal cord injury therapeutic focus.

Emerging players

  • Celavie Biosciences: Celavie develops human neural stem cell therapies for CNS disorders including Parkinson's disease, representing an emerging cell-therapy peer with overlapping CNS regenerative focus but more limited public visibility and capital.
  • BlueRock Therapeutics: BlueRock (a Bayer subsidiary) develops engineered iPSC-derived cell therapies for neurological diseases including Parkinson's. Comparable as a well-capitalized CNS cell therapy peer, though differentiated by pluripotent vs. progenitor cell source and genetic engineering.
  • Athersys: Athersys develops MultiStem®, an off-the-shelf allogeneic stem cell therapy evaluated in stroke and ARDS — comparable as a clinical-stage allogeneic cell therapy company, though focused on different CNS/critical care indications.

Broad incumbents

  • Amylyx Pharmaceuticals: Amylyx developed AMX0035/Relyvrio for ALS, a small-molecule alternative to cell therapy in the same primary indication. Comparable as a focused ALS therapeutic developer pursuing the same patient population with different modality.
  • Cytokinetics: Cytokinetics develops muscle-targeted small molecules (e.g., reldesemtiv/ tirasemtiv) for ALS and other neuromuscular diseases, competing for the same ALS patient population through a non-cell-therapy approach with broader pipeline scale.
  • Biogen: Biogen is a dominant neurology biopharmaceutical with major franchises in Multiple Sclerosis (Tysabri, Tecfidera) and ALS assets (Qalsody/tofersen). Represents the broad incumbent against which Q-Cells would compete in MS and ALS commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Q Therapeutics social profiles

Digital presence

Q Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Q Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Q Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q Therapeutics

What does Q Therapeutics do?

Q Therapeutics develops Q-Cells®, an allogeneic human glial progenitor cell therapeutic candidate designed to treat incurable central nervous system (CNS) diseases by delivering healthy glial-restricted progenitor cells to sites of CNS injury. Q-Cells® differentiate into astrocytes and oligodendrocytes to replace damaged myelin-producing and neuron-supporting cells, and are intended for treatment of transverse myelitis, ALS, multiple sclerosis, and spinal cord injury through injection-based administration. The company is clinical-stage with FDA-cleared Phase 1/2a trials in ALS and Transverse Myelitis.

Is Q Therapeutics a public or private company?

Q Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Q Therapeutics founded?

Q Therapeutics was founded in 2001. It employs 1 to 10 people.

Where is Q Therapeutics based?

Q Therapeutics is headquartered in Salt Lake City, United States, in the North America region.

Who are Q Therapeutics's main competitors?

Direct peers on record are BrainStorm Cell Therapeutics, Neuralstem (Seneca Biopharma), Lineage Cell Therapeutics and InVivo Therapeutics. Emerging players are Celavie Biosciences, BlueRock Therapeutics and Athersys. Broad incumbents are Amylyx Pharmaceuticals, Cytokinetics and Biogen.

Does Q Therapeutics have an API?

No public API is recorded for Q Therapeutics.

What industry is Q Therapeutics in?

Q Therapeutics's product category is Cell Therapy / Regenerative Medicine for CNS Diseases. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals